Biotech startup ecosystem
Europe's biotech ecosystem benefits from world-class research universities, strong IP frameworks, and growing specialist VC funds. The UK, Switzerland, and the Nordics are particularly strong in drug discovery, diagnostics, and synthetic biology. We track 106 organisations in this sector across 6+ countries.
Showing 81–100 of 106Biotech
Countries in this sector
Sectors alongside this one
Biotech results
Pharmacelera
Pharmacelera is a Barcelona-based computational drug discovery company headquartered at the Parc Cientific de Barcelona, combining computer-aided drug design, AI and machine learning, and high-performance computing to explore larger and more diverse chemical space. Its software suite, including PharmScreen, exaScreen, and PharmQSAR, helps pharma and biotech companies with target identification, hit identification, hit-to-lead, and lead optimization by finding novel hits and improving ligand binding properties. Clients referenced on its site include Sanifit Laboratoris and Wren Therapeutics.
Pikralida
Biotech drug-discovery company developing PKL-021, a small-molecule MMP inhibitor program for acute neuroprotection after stroke and traumatic brain injury, with additional applications in field-ready snakebite treatment.
Piotr Romanowski
Business Angel of the Year 2021 and former PwC partner, Piotr combines corporate finance expertise with deep-technology investing. He focuses on high-potential international projects, especially biotech and complex fintech products. His portfolio includes early-stage investments in biotechnology initiatives and specialized fintech tooling.
Pomerangels
A venture fund + angel network based in Szczecin, Pomerangels invests alongside business angels and syndicates in post-revenue companies. With a network of 100+ angels, they co-invest up to €4M in innovative SMEs across ICT, autonomous tech, biotech, etc. Notable focus: companies that already have strong angel syndicates; Pomerangels adds capital on top of angel rounds to scale these ventures.
PORT for Health: Oncology 2026
International healthtech and biotech conference hosted by Łukasiewicz – PORT, focused on cancer research, diagnostics, and therapy. Relevant for healthtech and biotech founders and researchers seeking R&D partners, clinical collaborators, and exposure to the Łukasiewicz innovation network.
Rodolphe Jenatton
Co-founder of Bioptimus and a machine-learning scientist who previously worked at Google DeepMind and Amazon on large-scale models, now applied to biological foundation models.
SagaNatura
SagaNatura is a Hafnarfjörður-based Icelandic biotech company producing premium natural ingredients from Iceland's pristine environment, including high-purity natural astaxanthin from microalgae and wild-grown organic Angelica Archangelica. The company traces its roots to SagaMedica (founded 2000) and KeyNatura (founded 2014), which merged to form the current entity. SagaNatura supplies nutraceutical ingredients to markets in North America and Asia-Pacific, and operates a consumer brand, KeyNatura, sold direct-to-consumer and through distributors worldwide. The company was tracking EUR 23 million in annual sales by 2025 and had been eyeing a potential IPO.
ScandiBio Therapeutics
ScandiBio Therapeutics is a Stockholm-based pharmaceutical company developing AI-driven drugs that target mitochondrial dysfunction, a factor implicated in neurodegenerative disorders and metabolic syndromes. Its lead product has entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer's disease, and has also completed Phase II trials in fatty liver patients and Phase III trials in COVID-19 patients. The company was founded by scientists affiliated with KTH Royal Institute of Technology, Karolinska Institutet, Sahlgrenska University Hospital, and King's College London.
Seroba Life Sciences
Seroba Life Sciences is a Dublin-based healthcare venture capital firm founded in 2002, investing in biotech, medical devices, and diagnostics across Europe with a focus on companies emerging from strong clinical and scientific foundations. The firm manages over EUR 300M and typically invests EUR 2-10M at Series A and B, taking board seats and providing strategic guidance on regulatory strategy and commercialization. Seroba has backed companies including Mainstay Medical, Aerogen, and Fire1, leveraging Ireland's deep life sciences talent pool and its proximity to major pharma and medtech multinationals headquartered in the country.
Sibylla Biotech
Sibylla Biotech is a preclinical-stage Italian biotech developing small-molecule protein degraders through a proprietary technology it calls Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT), powered by computer simulations and AI on its Oneiros platform. The company is a spin-off of INFN, the University of Trento, and the University of Perugia, co-founded by Emiliano Biasini and Pietro Faccioli. Sibylla has signed drug discovery collaborations with Takeda and Ono Pharmaceutical and raised a EUR 23 million Series A round in 2022 to advance its internal pipeline and expand its technology platform.
Sofinnova Partners
Sofinnova Partners is a life-sciences venture capital firm founded in 1972 and managing over EUR 4 billion. It invests from seed to later stage across biopharma, medtech, digital medicine, agriculture and industrial processes, running seven distinct investment strategies across the value chain.
Solar Foods
Solar Foods produces Solein, a single-cell protein made via gas fermentation using CO2, hydrogen and electricity — entirely decoupled from agriculture. Founded in 2017 as a VTT and LUT University spin-off, the company opened the world's first commercial-scale air-protein facility in Vantaa in 2024. In 2026 it is advancing its EFSA novel food approval and finalising the investment decision for Factory 02 in Lappeenranta, which will scale annual capacity from 160 to 6,400 tonnes. Fortum is a key investor and strategic partner for district heating integration.
Sophia Genetics
SOPHiA GENETICS is a Lausanne-based health-tech company founded in 2011 by Jurgi Camblong and Pierre Hutter as an EPFL spin-out. The company built a clinical AI platform — SOPHiA DDM — that enables hospital and laboratory networks to decode genomic data for oncology, rare disease, and pharmacogenomics applications. Its platform standardises and accelerates genomic analysis across a federated network of more than 780 healthcare institutions in 70 countries, turning each new clinical dataset into a contribution to a collectively smarter system. SOPHiA GENETICS listed on Nasdaq in July 2021, raising $228M, and is backed by Salesforce Ventures and Generation Investment Management. The company represents the EPFL ecosystem's capacity to produce globally significant clinical technology at scale.
Spinoff Europa Conference 2026
The 5th edition of Southeast Europe's flagship deep-tech and science-to-business conference, gathering 400+ speakers and around 40 breakthrough spinoff teams. It pairs university and research-spinoff founders with investors, clusters, and policymakers — strongly relevant for science-based founders raising early capital.
Spinoff Europa Conference 2027
The 6th edition of the Spinoff Europa Conference takes place in Sofia 17-18 June 2027. The event covers deep tech, biotech, greentech and AI, with a main conference programme, B2B matchmaking, 360-degree workshop labs and the Spinoff of the Year Award ceremony for Bulgaria's spinoff and deep-tech ecosystem.
Spore.Bio
Spore.Bio is a Paris-based biotech developing AI-driven microbiology testing for the food, beverage, cosmetics and pharmaceutical industries. Its technology uses spectroscopic analysis combined with machine learning to detect, quantify and identify micro-organisms directly from a sample without traditional culturing, enrichment or staining, reducing testing time from days to minutes. The approach is intended to let manufacturers identify contamination risks quickly on or near the production line. The company raised a $23M Series A in February 2025 led by Singular, building on an earlier pre-seed round, and in January 2026 announced multi-million funding from the Google.org Fund for AI in Science.
Starfish Bioscience
Restores soil health through AI-powered DNA sequencing of soil microbiomes, having built the first bacterial genome atlas for Bordeaux vineyard soils. Develops non-GMO, bacteria-based biosolutions to improve crop resilience in a changing climate.
Startup Braga
Innovation hub and accelerator supported by Microsoft, nurturing deep-tech startups in biotech, nanotech, and digital sectors. Provides acceleration, access to University of Minho labs, and corporate partners; backed 120+ companies. Scope: Regional (Northern Portugal).
Swiss Nordic Bio 2026
A high-level partnering and investor conference connecting life-science innovators, investors, and industry across Switzerland, Austria, and the Nordics. For a biotech or healthtech founder it provides structured 1-to-1 partnering meetings with investors and pharma in a focused single-day format.
Symbion
Symbion is one of Denmark's oldest science parks and incubators, founded to support research driven startups in tech and life science. It provides office space, labs, business services, and community programs for hundreds of early stage companies, and it hosts accelerators and investor events on site. Symbion is located in Copenhagen's innovation district and acts as a bridge between universities, corporates, and founders. Many Danish startups begin their journey inside the Symbion campus.
